Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002108 · ClinicalTrials.gov registry record · NA
3TC (Lamivudine; GR109714X) Open-Label Program
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002108: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002108 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002108, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3TC on markers of hepatitis B in co-infected patients at five to ten selected sites.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002108 record still lists
NCT00002108 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002108 about?
NCT00002108 is a clinical study titled "3TC (Lamivudine; GR109714X) Open-Label Program". To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3...
What is the current status of trial NCT00002108?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002108?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00002108?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.